Departments of Radiation Oncology.
Winship Cancer Institute, Emory University, Atlanta.
Am J Clin Oncol. 2019 Jan;42(1):36-41. doi: 10.1097/COC.0000000000000471.
Radical cystectomy currently remains the standard of care for muscle-invasive bladder cancer. However, surgery can be associated with considerable morbidity and mortality, including the removal of the bladder. An alternative strategy is to preserve the bladder through concurrent chemoradiation following a maximal transurethral resection of the tumor. National protocols using a bladder-preservation approach have demonstrated disease-specific outcomes comparable to radical cystectomy in selected patients, but these results have not been replicated in previously reported population-based series. Here, we describe an outcomes analysis of patients with muscle-invasive bladder cancer treated with either radical surgery or bladder-preserving chemoradiation (BPCRT) for those patients meeting BPCRT criterion using the National Cancer Database (NCDB).
Using the NCDB, patients with American Joint Commission on Cancer clinical T2-3, N0, M0 urothelial carcinoma diagnosed between 2004 and 2013 were included for analysis. Only patients treated with definitive intent with either radical cystectomy or concurrent chemotherapy and radiation after a maximal transurethral tumor resection were included. Propensity-score matching was used.
Among 8454 eligible patients, 7276 (86%) underwent radical cystectomy, and 1178 (14%) underwent BPCRT. Patients undergoing BPCRT were significantly older (median age, 77 vs. 68 y; P<0.001) and had higher Charlson-Deyo comorbidity scores (P=0.002). Using propensity-matched analysis, 1002 patients remained in each cohort, and there was no significant difference in survival found between the 2 cohorts (median overall survival, 2.7 vs. 3.0 y [P=0.20]; 4-year overall survival, 39.1% and 42.6% [P=0.15], for BPCRT and surgery, respectively). In addition, the hazard ratio (HR) of surgery versus BPCRT decreased over time, with an initial HR of 1.27 favoring BPCRT which decreased by a factor of 0.85 per year.
From 2004 to 2013, ∼14% of patients from the NCDB who potentially met bladder-preservation criteria underwent the procedure. Our propensity-matched analysis is the only report of its kind to demonstrate similar survival outcomes with bladder preservation when patients are properly selected. This study is also the first to demonstrate a dynamic HR between radical surgery and BPCRT over time.
根治性膀胱切除术仍是肌层浸润性膀胱癌的标准治疗方法。然而,手术可能会带来相当大的发病率和死亡率,包括膀胱切除。另一种策略是通过最大限度的经尿道肿瘤切除术,在肿瘤同步放化疗后保留膀胱。采用膀胱保留方法的国家方案已经证明,在选定的患者中,疾病特异性结果与根治性膀胱切除术相当,但这些结果在以前报告的基于人群的系列中尚未得到复制。在这里,我们使用国家癌症数据库(NCDB)描述了一组接受根治性手术或膀胱保留放化疗(BPCRT)治疗的肌层浸润性膀胱癌患者的结果分析,这些患者符合 BPCRT 标准。
使用 NCDB,纳入了 2004 年至 2013 年间诊断为美国癌症联合委员会临床 T2-3、N0、M0 尿路上皮癌的患者进行分析。仅包括接受根治性治疗的患者,包括根治性膀胱切除术或最大限度经尿道肿瘤切除术后同步化疗和放疗。采用倾向评分匹配。
在 8454 名合格患者中,7276 名(86%)接受了根治性膀胱切除术,1178 名(14%)接受了 BPCRT。接受 BPCRT 的患者年龄明显较大(中位年龄,77 岁 vs. 68 岁;P<0.001),Charlson-Deyo 合并症评分较高(P=0.002)。使用倾向匹配分析,每个队列仍有 1002 名患者,两组之间的生存无显著差异(中位总生存,2.7 岁 vs. 3.0 岁[P=0.20];4 年总生存率,分别为 39.1%和 42.6%[P=0.15])。此外,手术与 BPCRT 的风险比(HR)随时间而降低,最初有利于 BPCRT 的 HR 为 1.27,每年降低 0.85。
2004 年至 2013 年,NCDB 中约 14%有潜在膀胱保留标准的患者接受了该手术。我们的倾向匹配分析是唯一一种能够证明在适当选择患者的情况下,膀胱保留具有相似生存结果的报告。本研究也是第一个证明随着时间的推移,根治性手术与 BPCRT 之间的 HR 呈动态变化的研究。